Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

"Bridge the gap and accelerate India's advancements in innovative therapies"

Bio Spectrum

|

BioSpectrum India Oct 2024

Dr Ramesh Mundlamuri has over 19 years of experience in various biopharmaceutical organizations and has ample experience in various divisions and sections of the biopharmaceutical industry, including Research & Development, Technology Transfer, Commercial Manufacturing, Product & Process Development, Operations Management and so on.

"Bridge the gap and accelerate India's advancements in innovative therapies"

Prior to joining Duoning, he worked at Biological E in Hyderabad, India. In his role as Assistant General Manager, he led the commercial manufacturing of polysaccharide conjugate and protein-based Vaccines. Before that, he worked for Panacea Biotech, Sartorius, Sanofi and Krebs Biochemical Industries.

Dr Ramesh Mundlamuri is well-versed in cGMP, GLP, GDP and various regulatory bodies (WHO, EU, ROW, FDA, NRA). He also possesses extensive experience in the management of several vaccines, including polysaccharide vaccines, recombinant viral proteins, conventional vaccines and carrier protein.

Attributed to the BioE3 (Biotechnology for Economy, Employment and Environment) Policy, India's bioeconomy has seen exponential growth, ballooning from $10 billion in 2014 to a staggering $130 billion in 2024, with expectations to reach $300 billion by 2030. This policy also emphasizes the strategic objective of transitioning from chemical-based industries to sustainable bio-based models, promoting a circular bioeconomy. In this context, India has attracted numerous international biopharmaceutical companies to engage in business, which have absorbed a large number of local talents to better meet the demands of the domestic market. Dr Ramesh Mundlamuri joined Duoning Biotech (a comprehensive bioprocessing solutions provider) as the Head of Technology in 2023. In a discussion, he talked about the opportunities available in the Indian market and shared his insights and experiences in conducting bioprocessing business within the country.

We notice that most of Duoning's product offerings are centered around biomanufacturing, which may require customization or extensive testing. How do you provide support to local customers quickly and efficiently?

MEER VERHALEN VAN Bio Spectrum

Bio Spectrum

Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility

Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Motorica strengthens India presence with appointment of Kavinder Beniwal as COO

Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Cabinet approves major expansion of PG and UG medical education capacity

Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President

The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO

Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).

time to read

1 min

December 2025

Bio Spectrum

Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership

The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.

time to read

1 min

December 2025

Bio Spectrum

Bio Spectrum

"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"

Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;

time to read

4 mins

December 2025

Bio Spectrum

Bio Spectrum

"AI is a transformative enabler that's reshaping how science is conducted in labs"

2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:

time to read

4 mins

December 2025

Bio Spectrum

Bio Spectrum

Supporting India's Biopharma Expansion with Advanced, High-Performance Media

Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.

time to read

4 mins

December 2025

Bio Spectrum

Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging

Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.

time to read

1 min

December 2025

Listen

Translate

Share

-
+

Change font size